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Abstract
Major depressive disorder (MDD) has been associated with biased memory formation for mood-congruent information,
which may be related to altered monoamine levels. The piccolo (PCLO) gene, involved in monoaminergic
neurotransmission, has previously been linked to depression in a genome-wide association study. Here, we investigated
the role of the PCLO risk allele on functional magnetic resonance imaging (MRI) correlates of emotional memory in a sample
of 89 MDD patients (64 PCLO risk allele carriers) and 29 healthy controls (18 PCLO risk allele carriers). During negative word
encoding, risk allele carriers showed significant lower activity relative to non-risk allele carriers in the insula, and trend-wise
in the anterior cingulate cortex and inferior frontal gyrus. Moreover, depressed risk allele carriers showed significant lower
activity relative to non-risk allele carriers in the striatum, an effect which was absent in healthy controls. Finally, amygdalar
response during processing new positive words vs. known words was blunted in healthy PCLO+ carriers and in MDD
patients irrespective of genotype, which may indicate that signalling of salient novel information does not occur to the
same extent in PCLO+ carriers and MDD patients. The PCLO risk allele may increase vulnerability for MDD by modulating
local brain function with regard to responsiveness to salient stimuli (i.e. insula) and processing novel negative information.
Also, depression-specific effects of PCLO on dorsal striatal activation during negative word encoding and the absence of
amygdalar salience signalling for novel positive information further suggest a role of PCLO in symptom maintenance in
MDD.
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Introduction
Major depressive disorder (MDD) is a highly prevalent
psychiatric disorder, with twin studies showing that up to 40%
of MDD is genetically determined [1]. Phenotypically, depression
is characterized by depressed mood and/or anhedonia (loss of
interest in nearly all activities) and has been associated with
attentional deficits, resulting in poor functioning in daily life [2,3].
Symptoms of negative mood, lack of positive affect, and
attentional impairments may ensue from, or be reinforced by,
dysfunctional emotional memory processes. Phenotypic features of
abnormal perception, encoding, and consolidation of emotional
information, often seen in depression, may be moderated by
altered monoamine levels. Much of the candidate gene literature
has focused on genes from the monoaminergic neurotransmitter
system, such as the serotonin transporter, monoamine oxidase A
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and tryptophan hydroxylase 2 [4–9]. A recent study by our
consortium demonstrated that candidate genetic association
studies are not well replicated [10], which suggests that
a hypothesis-free approach is more useful to identify possible
genetic variants that contribute to MDD. A genome-wide
association study for MDD found the SNP rs2522833 located at
position 82453708 (hapmap genome build 37.1) in the piccolo
gene (PCLO), which is involved in monoaminergic neurotransmis-
sion, to be of particular interest in its genetic model [11]. This
association was confirmed in a number of studies with similar and
related phenotypes [12–17], but not in others [18–20]. The
rs2522833 SNP alters the hydrophilic, uncharged aminoacid
serine to the charged aminoacid alanine in the calcium-binding
C2A domain of PCLO and may affect protein stability [21]. The
PCLO protein is localized at the cytomatrix of the presynaptic
active zone and is important in monoaminergic neurotransmission
in the brain [13,20]. Recently, we have shown that the risk allele
on the piccolo gene in healthy controls and depressed patients was
associated with abnormal processing of negative emotional faces
rather than executive functioning [12]. However, whether the
rs2522833 polymorphism in the PCLO gene can also affect
emotional memory processing has not been studied yet.
On a cognitive-behavioural level, MDD has been associated
with attentional bias towards mood-congruent (i.e. negative)
information [22]. Using neuropsychological assessments [23], it
has been shown that negative emotional processing bias may be
predictive of depression symptoms and may represent a state
marker of MDD. It is thought that this negative bias is associated
with abnormal responsiveness of brain regions involved in emotion
processing, as well as disruption of cortico-limbic connections that
are important for regulating emotional responses [24]. Recently
we found an association of memory processing of positive and
negative information in MDD with altered activity in the
amygdala, ventral striatum, insula, hippocampus, anterior cingu-
late cortex (ACC), and inferior frontal gyrus (IFG) [25]. We found
left ventral insular activation specifically during processing of
negative words [25], which may reflect a general increased
sensitivity for negative information, as suggested by Surguladze
et al. (2010) [26]. In another study, an abnormal response for
recollecting negative faces was found in MDD patients, which may
reflect activation of negative schemas [27]. MDD has also been
associated with a mood-incongruent bias (i.e., away from positive
information) [28–30] which may affect memory formation for
positive as compared to negative and neutral stimuli. Using event
related potentials (ERP), Shestyuk et al. observed smaller slow
wave amplitudes to positive self-relevant words in MDD relative to
controls, whereas group differences for negative or neutral stimuli
were absent [30]. In summary, negative and positive biases may
lead to abnormal memory formation, reinforcing negative mood
and further contributing to a chronic course of the disorder
[31,32].
Recent studies have underscored the importance of PCLO in
MDD [13–16], and in neural processes underlying memory
formation [33]. Although we recently found evidence for the PCLO
risk allele to be associated with emotional processing of negative
faces, it remains unclear whether effortful classification of
emotional words is characterized by a similar association.
Moreover, it is unknown whether PCLO modulates negative bias
and emotional memory in depression.
Over the last few years, imaging genetics has shown to be
a powerful method for investigating neurobiological pathways in
various psychiatric disorders [34,35]. Using an intermediate
phenotype, such as emotional memory processing, which is
probably closer to the neurobiological substrate of MDD than
the clinical diagnosis itself [36], may be helpful in identifying
genetic risk alleles. Until now, imaging genetics studies on
emotional memory have mainly been conducted in healthy
controls and in psychiatric disorders other than MDD. We have
recently studied emotional processing and executive function in
the context of genetic association with PCLO in a group of MDD
patients and healthy controls [12] and found an association
increased amygdalar activity during the processing of negative
faces. Considering that encoding and retrieval of emotional stimuli
is a complex form of cognitive and emotional processing, we
hypothesize that the PCLO risk allele will also modulate emotional,
especially negative, memory processing. Focussing on the amyg-
dala, ventral striatum, hippocampus, anterior cingulate cortex
(ACC), insula, and inferior frontal gyrus (IFG), regions that are
important for encoding and recognition of valenced semantic
information, we studied functional MRI correlates of successful
emotional word encoding and recognition, and focussed on
activation patterns explained by PCLO genotype in these areas
independent of psychopathology. Since the pathophysiology of
MDD is complex and diverse, we also investigated whether PCLO
genotype effects on the brain were different in the presence of
MDD psychopathology. In addition, we controlled for the use of
selective serotonin reuptake inhibitors (SSRI) and tested whether
functional effects coincided with morphometric variations related
to PCLO genotype.
Methods
Participants
The present study was part of a large imaging study (details
described elsewhere [25]) included in the Netherlands Study of
Depression and Anxiety (NESDA) [37]. After excluding partici-
pants due to missing PCLO genotype data, technical problems
during scanning and/or insufficient task performance, our final
sample consisted of 89 MDD patients and 29 healthy controls (see
figure S1 in File S1 for a detailed flowchart of the numbers of
participants included). Exclusion criteria were: presence of MRI
contraindications, DSM-IV axis I disorder other than MDD,
Panic Disorder (PD) or Social Anxiety Disorder (SAD) (except
Generalized Anxiety Disorder/GAD) lifetime, or any DSM-IV
disorder (for HC), dependence or recent abuse of alcohol and/or
drugs, hypertension, major internal and/or neurological disorders,
and use of psychotropic medication (other than stable use of
a selective serotonin reuptake inhibitor [SSRI] or incidental use of
benzodiazepines). To assess depressive symptom characteristics
and severity scores, the Inventory of Depressive Symptomatology
(IDS) [38], and the Montgomery-A˚sberg Depression Rating Scale
(MADRS) [39], were used. PCLO groups did not differ with
regard to age, gender, education, MDD/HC ratio, depression
severity, or SSRI use/duration (see Table 1). All participants
provided written informed consent and the Ethics Committees at
the VU University Medical Center, and Academic Medical
Center, Amsterdam, the Leiden University Medical Center and at
the University Medical Center Groningen approved this study.
Genotyping
As described in detail elsewhere [11], genotyping was performed
by Perlegen. Observed genotypes in our sample did not deviate
from Hardy-Weinberg equilibrium (CC:AC:AA = 25:57:36; x2
[1] = 0.08; p.0.05). All subjects reported Western European
ancestry. We formed two groups based on the PCLO genetic
association study in MDD. One group consisted of participants
carrying the risk allele (AC/CC), and one group included
participants not carrying the risk allele (AA). In the following,
Effects of PCLO Genotype on Emotional Memory
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we will refer to these groups as PCLO+ (risk allele) carriers and
PCLO2 carriers, respectively.
Emotional Memory Task Paradigm
An event-related, (subject-paced), word encoding and recogni-
tion paradigm was used which has been described extensively
elsewhere [25]. During the encoding part, participants were asked
to classify 40 positive, 40 negative, and 40 neutral words according
to their valence. Words were presented pseudo-randomized
together with 40 baseline trials in 20 blocks of eight words. After
a brief retention interval, participants were asked to complete
a word recognition task. This task consisted of the 120 old
Table 1. Sample characteristics and task performance.
Group; mean (SD)
total (n = 118) PCLO+ (n = 82) PCLO2 (n = 36) p-value x2
Sample characteristics
Gender (%female) 61.9 (n = 73) 62.2 (n = 51) 61.1 (n = 22) 1 .012
Age (years) 38.1 (10.2) 37.5 (10.1) 39.3 (10.6) .42
Education (years) 12.6 (3.2) 12.9 (3.3) 12.0 (2.8) .16
Scancenter (% A, L, G) 28.8, 41.5, 29.7 26.8, 43.9, 29.3 33.3, 36.1, 30.6 .69 .747
Diagnosis (MDD/HC) 89/29 64/18 25/11 .36 .999
IDS (score) 18.8 (12.9) 19.7 (12.4) 16.9 (14.1) .28
MADRS (score) 12.5 (10.5) 13.4 (10.4) 10.3 (10.5) .14
Duration SSRI use (months) 18.9 (28.8) 14.5 (19.8) 32.0 (46.6) .17
SSRI use (no/yes) 90/28 61/21 29/7 .64 .525
Memory performance (p)
CREC.neg .685 (.138) .685 (.139) .685 (.135) .99
CREC.pos .725 (.132) .719 (.132) .739 (.132) .45
CREC.neu .69 (.166) .692 (.155) .688 (.191) .90
CREC.all .70 (.122) .697 (.122) .70 (.124) .83
FA.neg .17 (.11) .17 (.10) .18 (.11) .72
FA.pos .12 (.11) .13 (.11) .11 (.11) .35
FA.neu .07 (.06) .07 (.07) .06 (.06) .72
FA.all .124 (.079) .125 (.08) .119 (.079) .71
CREJ.neg .66 (.141) .66 (.137) .67 (.151) .623
CREJ.pos .70 (.175) .69 (.175) .72 (.175) .503
CREJ.neu .81 (.13) .81 (.13) .82 (.131) .699
CREJ.all .729 (.13) .72 (.127) .74 (.137) .54
Response time (sec)
rt SCR.neg 1.296 (.385) 1.311 (.411) 1.263 (.321) .63
rt SCR.pos 1.487 (.379) 1.507 (.384) 1.441 (.368) .45
rt SCR.neu 1.563 (.393) 1.567 (.415) 1.553 (.343) .69
rt CREC.neg 1.264 (.256) 1.265 (.237) 1.263 (.30) .61
rt CREC.pos 1.355 (.289) 1.37 (.291) 1.319 (.287) .27
rt CREC.neu 1.339 (.297) 1.335 (.276) 1.349 (.346) .90
rt FA.neg 1.50 (.45) 1.48 (.42) 1.53 (.50) .65
rt FA.pos 1.62 (.52) 1.59 (.41) 1.69 (.71) .37
rt FA.neu 1.58 (.53) 1.60 (.51) 1.53 (.57) .56
rt CREJ.neg 1.48 (.35) 1.50 (.33) 1.45 (.39) .52
rt CREJ.pos 1.52 (.34) 1.54 (.34) 1.50 (.35) .53
rt CREJ.neu 1.39 (.31) 1.40 (.31) 1.37 (.33) .61
Sample characteristics and task performance of the total sample. SD: standard deviation; n:number of participants; PCLO+: PCLO risk allele carriers; PCLO2: PCLO non-
risk allele carries; A: Amsterdam; L: Leiden; G:Groningen; MDD: major depressive disorder; HC: healthy controls; IDS: Inventory of Depressive Symptomatology; MADRS:
Montgomery-A˚sberg Depression Rating Scale; SSRI: Selective Serotonin Reuptake Inhibitors; p: proportion correct answers; neg: negative (words); pos: positive (words);
neu: neutral (words); sec: seconds; rt: response time.
Mean proportion correct and response times for encoding (subsequent hits) and recognition (hits, false alarms, correct rejection) indices. Correct RECognition (CREC):
correct recognition of a previously encoded word; False Alarm (FA): incorrect indication of a newly presented word as a previously encoded word; Correct REJection
(CREJ): correct recognition of a newly presented word as a new word; Subsequent Correct Recognition (SCR): consists of a word, presented during the encoding phase,
that is correctly recognized during the subsequent recognition phase.
doi:10.1371/journal.pone.0061494.t001
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encoding target words and 120 new distracter words (matched for
valence), and 40 baseline trials, presented pseudo-randomized in
20 blocks of 14 words. Participants had to indicate whether they
had ‘seen’ (i.e. remembered) the words previously, ‘probably seen’
(‘know’), or ‘not seen’ (rejection).
Magnetic Resonance Imaging Data Acquisition
The functional neuroimaging methods have been comprehen-
sively reported elsewhere [40,41]. In summary, T2*-weighted
echo-planar images (EPI) sensitive to the blood oxygenation level–
dependent (BOLD) effect were acquired using similar Philips 3T
MR systems (repetition time [TR] = 2300 ms, echo time
[TE] = 30.0 ms (UMCG: 28.0 ms), 35 slices (UMCG 39 slices)),
situated at different locations (Amsterdam, Leiden, and Gronin-
gen, the Netherlands).
The EPI volumes were acquired at 35 slices (UMCG: 39 slices),
interleaved axial acquisition, 3 mm thickness, matrix size 96696
(UMCG: 64664), in-plane resolution 2.2962.29 mm (UMCG:
363 mm). A T1-weighted anatomical MRI was also acquired for
each subject and included a sagittal 3-dimensional gradient-echo
sequence (TR = 9 ms, TE = 3.5 ms, matrix 2566256, voxel size:
16161 mm, 170 slices).
Statistical Analysis
Performance. Responses and response times were recorded
and were used to calculate proportions (p) Hits, correct rejections
(pCREJ), False Alarms (pFA), and old/new discriminant accuracy
(d’ = pHits-pFA), overall and per valence (negative, neutral, and
positive). Repeated-measures analyses of covariance (ANCOVAs)
were performed to test for effects of PCLO genotype, genotype6
diagnosis effects, and interaction effects of genotype, diagnosis and
genotype6diagnosis with valence on task performance (pHits_all,
pFalseAlarms_all, and d’_all) and response times during successful
encoding and successful recognition. Significance for behavioural
analyses was set at P,.05 and post hoc paired tests (T-test or
Mann-Whitney [U] were Bonferroni-corrected for multiple
comparisons (PBonferroni).
Imaging data analysis. Image processing was performed
using Statistical Parametric Mapping (SPM5; http://www.fil.ion.
ucl.ac.uk/spm/software/spm5; software implemented in Matlab
7.5.0 (The Matlab Inc, Natick, MA, USA). Details of preproces-
sing and first-level single-subject analyses have been described
elsewhere [25]. Briefly, following temporal and spatial preproces-
sing (final smoothing: 8 mm full-width at half-maximum
[FWHM]), data were analyzed in the context of the General
Linear Model. The subject-specific first-level models included
regressors for encoding and recognition events. Due to the small
proportion of recognition trials that were responded to with
a ‘know’ response, these responses were treated as ‘remembered’
and consequently added to either correct recognized (CREC) or
false alarms (FA). Activation maps associated with different
valences were calculated per subject. To avoid inclusion of non-
task related signal which might be expected when contrasting
against the repetitive lower baseline, contrast images with visual
input that only differed in its emotional content (‘encoding positive
. encoding neutral’, ‘encoding negative . encoding neutral’
resulting from the encoding phase, and ‘recognized positive .
recognized neutral’, and ‘recognized negative . recognized
neutral’ were likewise included in a second-level random-effect
analysis. Although our primary aim was to investigate valence
effects on processes of word encoding and recognition, we also
investigated specific effects of successful recognition by setting up
the following contrast: ‘correct recognition (hits) . correct
rejection’, resulting from the recognition phase) and included this
contrast in a second-level random-effect analysis.
Based on our previous study [25] we included the following
regions of interest for the emotional memory task, defined using
the Automated Anatomical Labeling (AAL) atlas or Talairach
Daemon (for the striatum) [42], implemented in the Wake Forest
University (WFU) Pick Atlas toolbox: amygdala, hippocampus,
ACC, IFG, insula, and striatum (includes caudate head, tail, body,
putamen). Main effects of task are reported at a threshold of
P,.05, whole-brain corrected for False Discovery Rate (FDR). We
conducted a full factorial using genotype and diagnosis as between
subject factors, and valence per encoding or recognition as within-
subject factor, to test whether the PCLO+ was associated with
altered activity in our ROIs for each valence for encoding or
recognition. Scan location was entered as covariate by means of
two dummy variables. Furthermore, to test for the specificity of
valence for correctly recognized old versus new words, we
conducted a 26263 ANOVA with genotype (PCLO+, PCLO2)
and diagnosis (MDD, HC) as between-subject factor, and valence
(positive, negative, and neutral; e.g. CREC_positive . CREJ_po-
sitive) as within-subject factor. Scan location was entered as
covariate by means of two dummy variables. Main effects of
genotype and interaction of PCLO genotype with current
psychopathology were reported at a voxel-wise threshold of
P,.05 FDR corrected for the regions of interest, with an initial
threshold of P,.001 uncorrected. In addition, to explore activity
common to both negative and positive vs. neutral stimuli we post
hoc computed the conjunction of these two contrasts, based on the
global null hypothesis (k$1) [43]. Each contrast had to meet
a threshold of P,.001 uncorrected. To test whether between-
group effects were related to volumetric differences, we conducted
a two-by-two ANOVA for those regions that showed a between-
group effect during the functional paradigm. Effects were reported
at a threshold of P,.05 FDR corrected for the region of interest.
To account for the number of a priori regions of interest, we
corrected the critical corrected p-value for the number of regions
(n = 6: amygdala, hippocampus, ACC, IFG, insula, and striatum).
Using a standard Bonferroni correction would be too stringent,
however, since the dependent variables were measured within the
same individuals. Therefore, we took this interdependency into
account and calculated the optimal threshold for positive vs.
neutral and negative vs. neutral encoding and recognition using
the Simple Interactive Statistical Analysis Bonferroni tool (www.
quantitativeskills.com/sisa/calculations/bonfer.htm). Response in
the six a priori regions of interest showed a mean correlation of
r = .75 during positive encoding (.neutral encoding) across all
participants, r = .63 (.neutral encoding) during negative encod-
ing, r = .84 (.neutral recognition) during positive recognition, and
r = .69 (.neutral recognition) during negative recognition, leading
to a critical alpha of.026,.032,.037, and.029, respectively (Table S2
in File S1). Because SSRI use may alter regional brain function in
psychiatric diseases [44], we repeated our analyses omitting SSRI
users, to test for possible effect of SSRI use.
Results
Sample Descriptives
Table 1 lists the sample characteristics and behavioural
statistics. Genotype groups were matched for MDD diagnosis,
age, gender, and education.
Behavioural analyses of the emotional word encoding and
recognition task revealed no significant main effect of genotype, no
genotype 6 valence, and no genotype 6 valence 6 diagnosis
interaction on accuracy and response time indices.
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PLOS ONE | www.plosone.org 4 April 2013 | Volume 8 | Issue 4 | e61494
Table 2 lists the genotype6 diagnosis sample and behavioural
characteristics.
Imaging Results
Main effects of the encoding and recognition contrast across
groups can be found in Table 3. Table S3 in File S1 describes the
main effects of encoding and recognition per valence.
A significant main effect of genotype was observed during
successful negative word encoding (‘encoding negative . encoding
neutral’) in the insular cortex (left insula; MNI [242 12 0];
Z = 3.92; right insula; PFDR = .008 corrected for small volume;
MNI [33 27 23]; Z = 4.26; PFDR = .007 corrected for small
volume; Figure 1; Table S4 in File S1) and trend-wise in the dorsal
part of the pregenual ACC and inferior frontal gyrus (left
pregenual ACC; MNI [23 33 30]; Z = 3.12; PFDR = .046
corrected for small volume; right pregenual ACC; MNI [9 33
18]; Z = 3.49; PFDR = .046 corrected for small volume; left IFG;
MNI [236 30 23]; Z = 3.41; PFDR = .045 corrected for small
volume; right IFG; MNI [33 30 26]; Z = 3.42; PFDR = .045
corrected for small volume; Figure 2; Table S4 in File S1). This
was due to lower activity in PCLO+ compared to PCLO2, which
was observed independent of diagnostic status. An interaction of
PCLO genotype and diagnosis was observed in the striatum (left
ventral striatum (caudate head); MNI [218 21 23]; Z = 3.6;
PFDR = .028 corrected for small volume; (caudate body); MNI [29
3 9]; Z = 3.3; PFDR = .028 corrected for small volume; right ventral
striatum (caudate body); MNI [9 0 15]; Z = 3.22; PFDR = .028
corrected for small volume; left dorsal putamen; MNI [218 329];
Z = 3.57; PFDR = .028 corrected for small volume; right dorsal
putamen; MNI [21 6 29]; Z = 4.65; PFDR = .002 corrected for
Table 2. Sample characteristics and task performance group6 diagnosis.
Group; mean (SD)
PCLO+ PCLO2
MDD (N=64) HC (N=18) MDD (N=25) HC (N=11)
Sample characteristics
Gender (%female) 65.6% (n = 42) 50.0% (n = 9) 60% (n = 15) 63.6% (n = 7)
Age (years) 35.9 (9.57) 43.2 (10.05) 39.0 (11.38) 40.0 (9.12)
Education (years) 12.4 (3.24) 14.7 (2.78) 11.3 (2.85) 13.6 (2.16)
Scancenter (% A, L, G) 23.4, 46.9, 29.7 38.9, 33.3, 27.8 24, 36, 40 54.5, 36.4, 9.1
IDS (score) 24.3 (10.03) 3.9 (3.26) 22.1 (13.29) 3.7 (3.43)
MADRS (score) 16.8 (9.12) 1.5 (2.18) 14.4 (9.82) .27 (.65)
Duration SSRI use (months) 14.5 (19.76) N/A 32.0 (46.59) N/A
SSRI use (no/yes) 43/21 18/0 18/7 11/0
Memory performance (p)
pCREC.neg .693 (.143) .658 (.127) .700 (.118) .652 (.170)
pCREC.pos .724 (.129) .700 (.145) .728 (.143) .764 (.103)
pCREC.neu .702 (.163) .656 (.114) .717 (.175) .621 (.219)
pFA.all .123 (.084) .132 (.067) .129 (.078) .099 (.079)
pCREJ.neg .658 (.136) .668 (.143) .655 (.146) .718 (.161)
pCREJ.pos .696 (.165) .701 (.212) .713 (.165) .739 (.205)
pCREJ.neu .807 (.136) .846 (.106) .800 (.142) .884 (.083)
Response time (sec)
rt SCR.neg 1.28 (.32) 1.32 (.57) 1.26 (.26) 1.24 (.37)
rt SCR.pos 1.53 (.39) 1.35 (.31) 1.43 (.36) 1.45 (.26)
rt SCR.neu 1.59 (.39) 1.47 (.45) 1.52 (.32) 1.54 (.31)
rt CREJ.neg 1.51 (.32) 1.48 (.35) 1.44 (.42) 1.50 (.35)
rt CREJ.pos 1.56 (.34) 1.49 (.34) 1.50 (.37) 1.50 (.33)
rt CREJ.neu 1.41 (.31) 1.40 (.30) 1.37 (.37) 1.37 (.24)
rt CREC.neg 1.26 (.21) 1.33 (.30) 1.23 (.30) 1.29 (.25)
rt CREC.pos 1.36 (.27) 1.42 (.31) 1.31 (.29) 1.30 (.24)
rt CREC.neu 1.31 (.25) 1.43 (.30) 1.31 (.31) 1.40 (.35)
Sample characteristics and task performance of the total sample, divided into genotype6diagnosis. SD: standard deviation; n:number of participants; PCLO+: PCLO risk
allele carriers; PCLO2: PCLO non-risk allele carries; A: Amsterdam; L: Leiden; G:Groningen; MDD: major depressive disorder; HC: healthy controls; IDS: Inventory of
Depressive Symptomatology; MADRS: Montgomery-A˚sberg Depression Rating Scale; SSRI: Selective Serotonin Reuptake Inhibitors; p: proportion correct answers; neg:
negative (words); pos: positive (words); neu: neutral (words); sec: seconds; rt: response time.
Mean proportion correct and response times for encoding (subsequent hits) and recognition (hits, false alarms, correct rejection) indices. Correct RECognition (CREC):
correct recognition of a previously encoded word; False Alarm (FA): incorrect indication of a newly presented word as a previously encoded word; Correct REJection
(CREJ): correct recognition of a newly presented word as a new word; Subsequent Correct Recognition (SCR): consists of a word, presented during the encoding phase,
that is correctly recognized during the subsequent recognition phase.
doi:10.1371/journal.pone.0061494.t002
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small volume. In the MDD group we found reduced activity in the
PCLO+ carriers relative to the PCLO2 carriers in this region,
which was absent in healthy controls (Figure 3).
Effects of genotype during successful recognition of negative
words did not meet the required threshold of P,.05 FDR
corrected. Subtreshold at P,.001 uncorrected, increased activity
in the insula in PCLO+ carriers relative to PCLO2 carriers was
observed (Table S4 in File S1).
During encoding of positive words or during recognition of
positive words effects of genotype likewise did not meet the
required a priori threshold. Exploration of these contrasts at
a threshold of P,.001 uncorrected revealed decreased activity in
frontal and limbic areas for encoding positive words (regions are
listed in table S4 in File S1).
During correct recognition.correct rejection (in the recognition
phase) of positive words we found a significant interaction of
emotion6diagnosis6genotype: During rejection of positive new
words, healthy PCLO2 carriers showed increased left amygdalar
activation, while no difference between processing positive old and
new words was observed in PCLO+ carriers and in MDD patients,
indicating blunting to novel positive information in PCLO+
carriers and patients (MNI [227 23 224]; Z = 3.36; Figure S5 in
File S1). No effect of negative or neutral words was found.
We tested post hoc for common valence effects by performing
a conjunction analysis, using both the negative and positive word
encoding contrasts. We found a PCLO genotype effect in regions
including IFG, medial frontal, insula, and caudate head (Figure 4),
reflecting reduced activity of the PCLO+ carriers relative to
PCLO2 carriers. It should be noted that our significant
conjunction (although at an explorative threshold of p,.001
uncorrected) does not mean all the contrasts were individually
significant (i.e., a conjunction of significance). It indicates that the
contrasts were consistently high and jointly significant. This is
equivalent to inferring one or more effects were present.
No volumetric differences were observed between groups in
these regions.
Effects of SSRI
After excluding SSRI users (n = 28), PCLO effects observed for
processing of emotional words memory (‘encoding negative vs.
encoding neutral, encoding positive vs. encoding neutral, recog-
nition negative vs. recognition neutral, and recognition positive vs.
recognition neutral’) were similar to the main genotype analyses.
Table 3. Main effects of encoding of emotional words vs. neutral words.
Emotional Encoding
Side BA MNI coordinates p (FDR) ka
Regions x y z Z
Frontal
Inferior Frontal Gyrus R 45 54 24 6 3.82 0.004 68
R 47 42 21 215 3.41 0.009 10
Medial Frontal Gyrus L 10 23 57 23 5.2 0.004 513
L 10 23 60 21 4.72 0.001 513
R 6 3 48 39 3.16 0.014 455
Middle Frontal Gyrus L 10 233 42 30 2.83 0.025 11
R 6 48 3 48 3.82 0.004 317
R 6 36 26 57 3.86 0.004 317
L 9 233 33 39 2.71 0.031 11
Temporal/Parietal
Precentral Gyrus L 6 230 29 54 5.29 0.001 4504
Anterior Cingulate L 32 26 27 30 3.61 0.006 226
R 24 6 18 33 3.31 0.01 226
Posterior Cingulate R 30 30 272 9 3.68 0.005 1574
Subcortical
Amygdala L N/A 224 3 224 2.74 0.032 10
Putamen L N/A 221 9 23 3.04 0.023 15
Cuneus L 30 215 272 9 3.56 0.011 394
Lingual Gyrus L 18 212 275 29 3.71 0.011 394
Inferior Parietal Lobule R 40 45 233 42 4.29 0.002 1574
Medial Dorsal Nucleus L thalamus 23 215 9 4.04 0.003 265
Middle Temporal Gyrus L 21 251 3 224 5.4 0.001 4504
Superior Temporal Gyrus R 38 48 6 227 3.25 0.012 19
Supramarginal Gyrus R 40 63 248 24 3.93 0.003 1574
Main effects of encoding of emotional words vs. neutral words. Main effects are reported at PFDR,.05, whole brain corrected with a minimum cluster size of 10. MNI:
Montreal Neurological Institute; BA: Brodmann area; k: clustersize; L: left; R: right; a: clustersize at p,.05 FDR whole brain corrected.
doi:10.1371/journal.pone.0061494.t003
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Figure 1. PCLO genotype effect during negative word encoding in the insula. PCLO+ carriers show significant hypoactivation of the insula,
relative to PCLO2 carriers during negative word encoding. Panel A shows sagittal, coronal, and axial section at peak activation (green circle: insula;
results shown at P,.005; Z = 3.92 (left), Z = 4.26 (right)). Panel B shows the cluster means for each peak voxel, with their standard errors for the
different groups. PCLO: Piccolo genotype; PCLO+: PCLO risk allele carriers; PCLO2: PCLO non-risk allele carriers; MDD: Major Depressive Disorder; HC:
Healthy controls; AU: arbitrary units.
doi:10.1371/journal.pone.0061494.g001
Figure 2. PCLO genotype effect during negative word encoding in the inferior frontal gyrus and anterior cingulate cortex. PCLO+
carriers show trend-wise hypoactivation of the inferior frontal gyrus and anterior cingulate cortex relative to PCLO2 carriers during negative word
encoding. Panel A shows sagittal, coronal, and axial section at peak activation (black circle: IFG, red circle: dorsal part of pgACC; results shown at
P,.005; IFG, Z = 3.79 (left), Z = 3.42 (right); pgACC, Z = 3.12 (left), Z = 3.49 (right)). Panel B shows the cluster means for each peak voxel, with their
standard errors for the different groups. PCLO: Piccolo genotype; PCLO+: PCLO risk allele carriers; PCLO2: PCLO non-risk allele carriers; MDD: Major
Depressive Disorder; HC: Healthy controls; AU: arbitrary units.
doi:10.1371/journal.pone.0061494.g002
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Discussion
In the present study, we examined the effects of the PCLO
rs2522833 polymorphism on regional brain activation during
performance of an emotional word encoding and recognition
paradigm in MDD patients and healthy controls, while also
controlling for SSRI use and volumetric differences. Just below
threshold, results indicated that PCLO is associated with
psychopathology-independent functional changes within the dor-
sal part of the pregenual (pg)ACC, predominantly during
processing of novel, negative information. Whereas pgACC
hypoactivation in PCLO+ carriers was specific for the processing
of negative information, we found that the PCLO risk allele
modulated both negative and positive information processing in
the IFG and insula. In addition, PCLO was found to differentially
affect striatal activation during negative encoding in health and
disease, as genotype effects were observed in MDD patients but
not in controls. Successful recognition of emotional words was not
associated with significant PCLO effects. To avoid problematic
Figure 3. Genotype6diagnosis interaction during negative word encoding in the striatum. PCLO+ carriers within the MDD group show
reduced striatal activity relative to the PCLO2 carriers within the MDD group during negative word encoding. No effect of genotype is seen in the HC
group. Panel A shows sagittal, coronal, and axial section at peak activation (results shown at P,.005; black circle: dorsal putamen, Z = 4.65 (right).
Panel B shows the cluster means for each peak voxel, with their standard errors for the different groups. PCLO: Piccolo genotype; PCLO+: PCLO risk
allele carriers; PCLO2: PCLO non-risk allele carriers; MDD: Major Depressive Disorder; HC: Healthy controls; AU: arbitrary units.
doi:10.1371/journal.pone.0061494.g003
Figure 4. Valence specific effects during word encoding. Panel A shows valence specific effects during word encoding (results shown at
P,.005). Black circle: inferior frontal gyrus (right); MNI [x = 36 y = 27 z =23], Z = 3.9. Panel B: Parameter estimates and 95% confidence intervals
showing direction of effect for each valence during word encoding in peakvoxel (MNI [x = 36 y = 27 z =23]). PCLO: Piccolo genotype; PCLO+: PCLO
risk allele carriers; PCLO2: PCLO non-risk allele carriers; MDD: Major Depressive Disorder; HC: Healthy controls; AU: arbitrary units.
doi:10.1371/journal.pone.0061494.g004
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interpretation of genotype effects on memory processing [45,46],
memory performance was modelled at first level. Moreover, we
found a blunted effect in the amygdala in PCLO+ carriers and
MDD patients of new positive words relative to old words, which
may indicate that signalling of salient novel information does not
occur to the same extent in PCLO+ carriers and MDD patients.
During recognition of negative or neutral words, no difference
between PCLO+ and PCLO2 was found. We found no effect of
PCLO genotype, or PCLO 6 MDD interaction during perfor-
mance.
To our knowledge, this is the first genetic neuroimaging
association study in MDD and healthy controls that shows an
effect of PCLO genotype related hypoactivation of insula, and
trend-wise of ACC and IFG during emotional memory processing.
In a previous study, we showed that the PCLO risk allele is
associated with abnormal involvement of limbic regions in
response to negative stimuli (i.e. emotional faces), but not with
altered prefrontal recruitment during an executive control task
[12]. In the present study, we extended these findings by showing
that in PCLO+ carriers, processing of negative information (words)
is characterized by reduced insula, and trend-wise pgACC and
IFG activation. These regions are considered important regions in
the production and effortful regulation of mood states, and have
been consistently associated with the psychopathology of MDD
[47]. Moreover, the insula has been implicated in the salience
network [48], where it is considered an important hub for
processing salient events for action to be initiated, including calling
on attentional resources and regulating autonomic activity in
reaction to salient stimuli [49]. Although near-significant only, the
present results demonstrate that PCLO impacts on processing of
negative information in the dorsal part of the pgACC in both
healthy controls and depressed patients. Our finding that PCLO
genotype modulates the processing of negative novel information
specifically in the pgACC replicates results obtained in healthy
controls [50–52]. Therefore, these findings indicate that biases
towards negative stimuli, as reflected in altered pgACC activation,
may represent not only a feature of MDD, but also a vulnerability
factor for developing mood disorders [53].
Taken together, this suggests that PCLO genotype may increase
the risk for developing or maintaining a depressive disorder by
affecting the mood regulating capacity of the brain.
In contrast to these psychopathology-independent findings,
decreased activity in the ventral striatum during processing of
negative stimuli was found in MDD patients only. MDD has been
associated with altered striatal function [54], and with reward
processing [55]. Since reduced serotonergic pathway signalling in
the striatum was recently associated with MDD [56], it suggests
a mediating effect of PCLO in MDD. Also, these findings are
consistent with a recent proposition that PCLO may be
particularly relevant for reward processing deficits in the context
of stress [57].
We found that processing of emotional words, irrespective of
valence, was modulated by the PCLO risk allele in regions
including insula, IFG, caudate head, and medial frontal gyrus, as
shown when performing a conjunction analysis. Low caudate
activity has previously been associated with both altered inhibition
of negative stimuli in subjects at risk for MDD [58] and
motivational pathway dysfunction, or the inability to experience
pleasure or engage in rewarding activities [59]. We propose that
lower insula, and IFG activity in PCLO+ carriers may reflect
a general inadequacy for regulating emotional responsiveness,
either to enhance or induce a positive emotional mood state, or to
down regulate negative mood states, increasing vulnerability for
MDD in PCLO+ carriers.
In the present study, no effect of genotype during successful
recognition was found. However, we found a blunted activity in
the amygdala in healthy PCLO+ carriers and in MDD patients
irrespective of genotype during recognition of new positive words,
relative to old words, which underlines that new positive
information results in less salience signalling in the amygdala in
PCLO risk allele-carriers. This neural variation in processing novel
positive information may further contribute to development of
MDD symptomatology, as novel positive information appears to
go undetected and may therefore further contribute to a negative
biased orientation towards the world. Nevertheless, results
suggested that PCLO may play a modest role in biased processing
of familiar information: in PCLO+ carriers, processing of negative
familiar information was associated with insular hyper-activation,
as well as hypo-activation in a network implicated in reward
processing and learning (including the inferior and medial frontal,
hippocampal, caudate head, insula, and putamen), compared to
non-risk carriers. However, given that these latter results were
subtreshold only, we may conclude that PCLO predominantly
affects deep processing during of semantic classification and
successful encoding of novel information, which is indirect
supported by animal studies showing that novel information
contributes to fear aspects of depressive-like behaviour (i.e. the
depression phenotype) [60].
In the present study, similar results were obtained when
repeating our main analyses after excluding SSRI users, which is
in line with previous findings in an emotional face processing task
[12]. The recent proposal that PCLO enhances the neurophys-
iologic response to SSRIs in MDD patients [16] is not supported
by our study.
Some limitations should be noted. First, although we used
similar 3T systems at each site in this multicenter study, no
systematic scanning site 6 diagnosis bias occurred. However,
variability in image acquisition may have occurred due to minor
differences in hardware (receiver coil), imaging parameters, and
timing of software upgrades. Second, depression severity in our
MDD patients was only mild to moderate, due to recruitment
from the general population, general practitioners, and outpatient
mental health organizations, but not from inpatient clinics.
Consequently, we do not know whether our interaction findings
would have been more robust when inpatients had also been
included. Third, cell sizes were small when testing for genotype6
group interactions, which may have biased our results. To increase
cell sizes in neuroimaging genetic studies using GWAS as
genotypic factor, correction for multiple testing requires very
large sample sizes (including healthy controls), which is only
feasible in a multicenter meta-analysis approach [61]. However,
the present study was a follow-up of a previous GWAS for the
clinical phenotype of MDD, testing only a single promising
polymorphism in the PCLO gene.
Although this study provides evidence for modulation of
negative word encoding related activity by PCLO genotype, its
role in the serotonergic pathway remains unclear and should be
the focus of future research. A promising approach is likely to be
the use of positron emission tomography (PET) tracers to study
radioligand binding to receptors that interact with PCLO, as
shown when studying genes associated with serotonin transporter
function [62]. In addition, the use of longitudinal MRI designs
may be helpful to investigate whether PCLO+ carriers continue to
show a negative bias reflected in lower frontostriatal activity and
therefore may, indeed, be more vulnerable to develop MDD.
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Conclusion
Our findings indicate that the presence of the PCLO risk allele
may increase vulnerability for MDD by affecting the mood
regulating capacity of the brain and by influencing dysfunctional
reward processing in MDD. It further increases vulnerability for
MDD by contributing to a general inadequacy for regulating
emotional responsiveness. The interaction between the PCLO
genotype and MDD reflected in decreased activity in the ventral
striatum and amygdala also suggests that the pathophysiology of
MDD is complex and may interact with the PCLO genotype.
Moreover, we have found similar regions as MDD studies during
emotional encoding, which indicates that the PCLO risk allele plays
an important role in the mediation between MDD and altered
brain activity.
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